Company Shuttle Pharmaceuticals Holdings, Inc.

SHPH

US8256932034

Pharmaceuticals

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:00:01 29/05/2024 am IST			5-day change	1st Jan Change
0.4438 ^USD	+6.97%		+3.69%	-2.46%

21/03	Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
07/02	Shuttle Pharmaceuticals Holdings, Inc. announced that it expects to receive $2.25 million in funding	CI

Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company. The Company is focused on improving the outcomes of cancer patients treated with radiation therapy (RT). It is developing a pipeline of products designed to address cancer therapies as well as to extend to the new applications of radiation therapy. Its product candidates include Ropidoxuridine (IPdR), Ropidoxuridine and Tipracil (IPdR/TPI), SP-1-161, SP-2-225, and SP-1-303. Ropidoxuridine (IPdR) is its lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. Ropidoxuridine and Tipracil (IPdR/TPI) is undergoing preclinical development for use as a radiation sensitizer for rectal cancers. SP-1-161 is a pre-clinical candidate lead histone deacetylase (HDAC) inhibitor, a radiation sensitizing candidate product. SP-2-225 is a pre-clinical class II b selective HDAC inhibitor that affects histone deacetylase HDAC6.

Number of employees: 8

Managers	Title	Age	Since
Mira Jung FOU	Founder	75	18/12/18
Anatoly Dritschilo CEO	Chief Executive Officer	80	18/12/18
Hoek Vander DFI	Director of Finance/CFO	65	01/18/01
Peter Dritschilo PSD	President	55	18/12/18
Tyvin Rich CTO	Chief Tech/Sci/R&D Officer	77	-

Members of the board	Title	Age	Since
Anatoly Dritschilo CEO	Chief Executive Officer	80	18/12/18
Peter Dritschilo PSD	President	55	18/12/18
Milton Brown FOU	Founder	59	18/12/18
Mira Jung FOU	Founder	75	18/12/18
Chris Senanayake BRD	Director/Board Member	67	01/21/01
Joshua Schafer BRD	Director/Board Member	53	01/19/01
Steven Richards BRD	Director/Board Member	56	01/19/01
Bette Jacobs BRD	Director/Board Member	73	28/22/28

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	16,794,893	9,219,256 ( 54.89 %)	0	54.89 %

Name	Equities	%	Valuation
Anatoly Dritschilo 25.54 %	4,289,607	25.54 %	2 M $
Milton Brown 6.518 %	1,094,610	6.518 %	436 749 $
Mira Jung 6.379 %	1,071,388	6.379 %	427 484 $
Amir Heshmatpour 3.556 %	597,149	3.556 %	238 262 $
Ayrton Capital LLC 1.312 %	220,426	1.312 %	87 950 $
William Adkins 1.096 %	184,071	1.096 %	73 444 $
Hoek Vander 0.6184 %	103,852	0.6184 %	41 437 $
Geode Capital Management LLC 0.2200 %	36,957	0.2200 %	14 746 $
Renaissance Technologies LLC 0.0982 %	16,500	0.0982 %	6 584 $
Bette Jacobs 0.0905 %	15,201	0.0905 %	6 065 $

Shuttle Pharmaceuticals Holdings, Inc.

401 Professional Drive Suite 260

20879, Gaithersburg

http://www.shuttlepharma.com

address Shuttle Pharmaceuticals Holdings, Inc.(SHPH)

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
SHUTTLE PHARMACEUTICALS HOLDINGS, INC.	-2.46%	7.46M
ELI LILLY AND COMPANY	+38.59%	727B
JOHNSON & JOHNSON	-7.89%	347B
MERCK & CO., INC.	+15.66%	319B
ABBVIE INC.	+0.24%	274B
ASTRAZENECA PLC	+13.28%	238B
NOVARTIS AG	+7.14%	204B
ROCHE HOLDING AG	-6.18%	203B
AMGEN INC.	+4.23%	161B
PFIZER, INC.	-1.70%	160B